Exelixis, Inc. (EXEL) News
Follow Exelixis, Inc. (EXEL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Exelixis reports quarterly results for period ended September 30
A machine-generated LSEG summary reports Exelixis' results for the quarter ended September 30.
EQUITY | Oct 29, 2026, 10:37 PM UTC
M
Exelixis Q3 Revenue, Adjusted Net Income Beat Estimates
EQUITY | Oct 29, 2026, 08:24 PM UTC
M
Exelixis Q3 net income rises 13% to $218.1 million
EARNINGS | Oct 29, 2026, 08:23 PM UTC
M
Exelixis Q3 Diluted EPS Rises 23%; Revenue Up 10%
Exelixis said third-quarter 2026 diluted earnings per share rose 23%, while revenue increased 10%.
EQUITY | Oct 29, 2026, 08:22 PM UTC
M
Exelixis Reports Q3 Revenue of $658.7M Versus $646.5M Estimate
EQUITY | Oct 29, 2026, 08:17 PM UTC
M
Exelixis Posts Q3 Adjusted EPS of $0.94 per Share
Exelixis reported Q3 adjusted EPS of $0.94 per share, versus the FactSet estimate of $0.89.
EARNINGS | Oct 29, 2026, 08:17 PM UTC
L
Exel, Suzlon Extend Collaboration With Multi-Year Supply Deal
Exel Composites Oyj OMXHEX:EXEL
NEWS | Sep 24, 2026, 05:07 AM UTC
L
EXEL: Zanzalintinib advances as a multi-indication franchise amid strong cabozantinib growth and targeted AI use
China-originated innovation and policy risks are shaping strategy, with a focus on novel assets and targeted AI use. Cabozantinib's growth and exclusivity are defended, while zanzalintinib is poised for multi-indication
GEOPOLITICS | Sep 15, 2026, 05:14 PM UTC
L
EXEL: Disciplined innovation and franchise expansion drive growth, with zanzalintinib poised for major launches
Revised summary: The discussion emphasized disciplined innovation, focusing on novel assets, AI-driven analytics, and franchise-building. Cabozantinib's growth and exclusivity support the shift to zanzalintinib, advancin
NEWS | Sep 15, 2026, 04:39 PM UTC
L
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
Shares of Exelixis (EXEL) fell 2% on Friday after the company said U.S. regulators added three months to the review of its next cancer drug, but William Blair still sees a low chance of an outright rejection.The Food and
REGULATION | Sep 11, 2026, 08:19 PM UTC
L
EXEL outlines growth priorities across RCC, NETs and upcoming launches
EXEL says it plans to expand product franchises in RCC and NETs. It cites CABOMETYX steady market share gains and highlights zanzalintinib launch timing in CRC and NETs, supported by AI-driven efficiency and capital allo
EQUITY | Sep 09, 2026, 02:18 PM UTC
L
EXEL: Expanding franchises, clinical innovation, and AI-driven efficiency fuel growth and market leadership
Key priorities include expanding product franchises in RCC and NETs, with CABOMETYX and zanzalintinib driving growth through new indications and robust clinical development. Market share gains, disciplined R&D spending,
EQUITY | Sep 09, 2026, 01:45 PM UTC
L
Adagene and Exelixis reach milestone in SAFEbody ADC collaboration
Adagene announced it achieved a milestone in its ongoing collaboration with Exelixis to advance SAFEbody antibody-drug conjugate candidates.
GEOPOLITICS | Sep 09, 2026, 12:01 PM UTC
L
Exel cites CABO and zanza progress, aiming for CRC launch readiness
Exel says CABO growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. It flags zanza for immediate CRC launch, citing clinical data and an expanded sales force.
EQUITY | Sep 08, 2026, 04:45 PM UTC
M
EXEL outlines transition strategy through 2026, leveraging CABOMETYX
Management outlined a transition strategy through 2026: maximize CABOMETYX and invest in zanzalintinib to offset post-2031 LOE. CABOMETYX targets $3B peak sales; zanzalintinib is launch-ready for CRC, with capital alloca
EQUITY | Sep 08, 2026, 04:09 PM UTC
L
Exelixis to webcast fireside chats at September investor conferences
Exelixis, Inc. said management will participate in fireside chats at investor conferences in September, with webcast links available via the Investors & News event calendar page.
EQUITY | Sep 01, 2026, 08:05 PM UTC
M
Exelixis FDA approval barred until at least Jan 15, 2030
Exelixis won an appeals court ruling upholding key patents, with FDA approval barred until at least Jan 15, 2030.
REGULATION | Aug 31, 2026, 08:24 PM UTC
L
Exelixis earliest MSN launch for proposed U.S. generic set for Jan. 15, 2030
Exelixis says that, given its decision, the earliest MSN it can launch a proposed generic product in the U.S. is Jan. 15, 2030.
EQUITY | Aug 31, 2026, 06:31 PM UTC
L
U.S. appeals court affirms patent-suit portion against MSN Labs
Exelixis says a U.S. appeals court affirmed a portion of its patent suit against MSN Laboratories.
EQUITY | Aug 31, 2026, 06:31 PM UTC
M
Near 50dma resistance TIGO FICO LEN AFRM ESS DOC CXT FIS EXEL AN CNC CZR COST USB STZ BPOP BRKB CTVA ORCL DD TSLA PB MTB KR CL EWBC MCD AMG
Near 50dma resistance TIGO FICO LEN AFRM ESS DOC CXT FIS EXEL AN CNC CZR COST USB STZ BPOP BRKB CTVA ORCL DD TSLA PB MTB KR CL EWBC MCD AMG RF MLI PFG CASY OTIS FCN TPL CAH SFM SBAC NVR
EQUITY | Aug 21, 2026, 06:36 PM UTC
L
BMO starts EXEL at Market Perform, sets $54 target
BMO initiates coverage of EXEL with a Market Perform rating and a $54 price target.
EQUITY | Aug 19, 2026, 11:50 AM UTC
L
Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est
Exelixis (NASDAQ: EXEL ) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 billion-$2.550 billion vs $2.595 billion estimate.
EARNINGS | Aug 05, 2026, 08:23 PM UTC
L
Citizens healthcare analysts hold an analyst/industry conference call
Citizens healthcare analysts hold an analyst/industry conference call
EQUITY | Jul 13, 2026, 08:56 AM UTC
L
Exelixis shares are trading higher after UBA raised its price target on the stock from $43 to $52.
Exelixis shares are trading higher after UBA raised its price target on the stock from $43 to $52.
EQUITY | Jul 02, 2026, 03:11 PM UTC
L
UBS Maintains Neutral on Exelixis, Raises Price Target to $52
UBS analyst Ashwani Verma maintains Exelixis (NASDAQ: EXEL ) with a Neutral and raises the price target from $43 to $52.
EQUITY | Jul 02, 2026, 12:56 PM UTC
L
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ: EXEL ) with a Buy and maintains $56 price target.
EQUITY | Jul 02, 2026, 10:49 AM UTC
M
EXEL: Citizens Raises Target
Citizens maintains Market Outperform on Exelixis and raises price target to $55
EQUITY | Jun 24, 2026, 01:02 PM UTC
M
EXEL Reports STELLAR-303 Results
Exelixis reports final STELLAR-303 analysis showing non-significant OS trend favoring zanzalintinib and Tecentriq combo in non-liver metastases mCRC
EARNINGS | Jun 22, 2026, 12:15 PM UTC
M
EXEL Updates STELLAR-303 Trial
Exelixis provides update on the Phase 3 STELLAR-303 trial evaluating Zanzalintinib in combination with an immune checkpoint inhibitor in patients with metastatic colorectal cancer
EARNINGS | Jun 22, 2026, 12:01 PM UTC